ARIA (Atacand Renoprotection In NephropAthy Pt.)

Summary

To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment

Timeline

Start

2007-12

Primary completion

2009-08

Completion

2009-08

Drugs

Indications